Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11787796 Plasma Kallikrein inhibitors and uses thereof

Patent 11787796 was granted and assigned to Takeda Pharmaceutical Company on October, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Takeda Pharmaceutical Company

Current Assignee

Takeda Pharmaceutical Company

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

John Mark Ellard

Jeremy Mark Travins

Alastair Rae

Nikolaos Papaioannou

Sarah Jocelyn Fink

Date of Patent

October 17, 2023

Patent Application Number

17024437

Date Filed

September 17, 2020

Patent Citations

US Patent 10730874 Inhibitors of plasma kallikrein and uses thereof

US Patent 7166596 Heterocyclic aromatic compounds useful as growth hormone secretagogues

US Patent 8153658 Piperidine derivative or salt thereof

US Patent 10259803 Therapeutic inhibitory compounds

US Patent 10301284 Therapeutic inhibitory compounds

US Patent 11370803 Heteroaryl plasma kallikrein inhibitors

Patent Citations Received

US Patent 12065448 Heteroaryl plasma kallikrein inhibitors

0

Patent Primary Examiner

CPC Code

Patent abstract

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11787796 Plasma Kallikrein inhibitors and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool